SCHEMBL504322

SCHEMBL504322

Cc1ccccc1-c1c(O)ccc2[nH]nnc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.39
RAB9A P51151 5/20 0.39
SMN1; SMN2 Q16637 5/20 0.39
MAPT P10636 4/20 0.39
ALOX15 P16050 3/20 0.39
USP2 O75604 2/20 0.39
NFKB1 P19838 2/20 0.39
NFKB2 Q00653 2/20 0.39
RELA Q04206 2/20 0.39
TSHR P16473 1/20 0.39
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
GAA P10253 4/20 0.38
MGAM O43451 3/20 0.38
SI P14410 3/20 0.38
MGAM2 Q2M2H8 3/20 0.38
NPC1 O15118 4/20 0.37
NPSR1 Q6W5P4 3/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31625576 1.00 HPGD (0.39) HPGDRAB9ASMN1; SMN2MAPTALOX15
SCHEMBL28596106 0.84 GAA (0.40) HPGDRAB9ASMN1; SMN2MAPTALOX15
SCHEMBL15020493 0.82 MGAM (0.41) HPGDRAB9ASMN1; SMN2MAPTALOX15
SCHEMBL7645989 0.82 GAA (0.38) HPGDRAB9ASMN1; SMN2TSHRKMT2A
SCHEMBL719445 0.79 DHFR (0.38) MCL1CYP1A2KDM4E
SCHEMBL29359068 0.78 CHEK1 (0.37) MAPTCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL80394 0.78 CHEK1 (0.37) MAPTCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL28674437 0.77 GAA (0.35) HPGDRAB9ASMN1; SMN2GAANPC1
SCHEMBL28925106 0.77 MEN1 (0.33) HPGDSMN1; SMN2MEN1KMT2AMCL1
SCHEMBL6897857 0.76 CHEK1 (0.36) MAPTCYP1A2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240173229-A1 METHODS OF SKIN WHITENING BY USE OF CANOLA EXTRACTS 1242753 ONTARIO INC (CA) 2024-05-30 US claimed
EP-4223279-A1 METHODS OF SKIN WHITENENING BY USE OF CANOLA EXTRACTS 1242753 Ontario Inc. (CA) 2023-08-09 EP claimed
EP-2061308-B1 A WATER BASED CLEAR SUNSCREEN AND INSECT REPELLENT COMPOSITION AVON PROD INC (US) 2014-01-22 EP claimed
US-7744911-B2 Water based clear sunscreen and insect repellent composition AVON PRODUCTS, INC (US) 2010-06-29 US claimed
US-20090311208-A1 Oil In Silicone Emulsions and Compositions Containing Same AVON PRODUCTS, INC. (US) 2009-12-17 US claimed
WO-2009129855-A1 PHOTOPROTECTIVE COMPOSITIONS CONTAINING PEPTIDES UNITED TECHNOLOGIES UT AG (CH) 2009-10-29 WO claimed
EP-2061308-A2 A WATER BASED CLEAR SUNSCREEN AND INSECT REPELLENT COMPOSITION AVON PRODUCTS, INC. (US) 2009-05-27 EP claimed
EP-1784158-A4 IMPROVED TOPICAL SKIN CARE COMPOSITIONS AVON PROD INC (US) 2009-03-11 EP claimed
WO-2008024738-A2 A WATER BASED CLEAR SUNSCREEN AND INSECT REPELLENT COMPOSITION AVON PRODUCTS, INC. (US) 2008-02-28 WO claimed
US-20080050409-A1 Water based clear sunscreen and insect repellent composition AVON PRODUCTS, INC 2008-02-28 US claimed
WO-2003051279-A2 TOPICAL COMPOSITIONS AND METHODS OF APPLICATION AVON PRODUCTS, INC. (US) 2003-06-26 WO claimed
WO-2003051318-A1 PHOTOSTABLE SUNSCREEN COMPOSITIONS AND METHODS OF STBAILIZING AVON PRODUCTS, INC. (US) 2003-06-26 WO claimed
US-20030099679-A1 Extended duration insect repellent composition and method of application to the skin CITIBANK, N.A., LONDON BRANCH 2003-05-29 US claimed
US-6555095-B1 Containing a compound: L-A-H and A-L-H, wherein L is a lipophilic moiety, wherein A is an aromatic moiety having an ultraviolet absorption maximum between 290 nanometers and 400 nanometers, and wherein H is a hydrophilic moiety AVON PRODUCTS, INC. 2003-04-29 US claimed
EP-1250043-A4 EXTENDED DURATION INSECT REPELLENT COMPOSITION AND METHOD OF APPLICATION TO THE SKIN AVON PROD INC (US) 2003-04-02 EP claimed
US-6531118-B1 Topical compositions with a reversible photochromic ingredient AVON PRODUCTS, INC. 2003-03-11 US claimed
US-6517816-B1 Inner discontinuous phase and an outer continuous phase AVON PRODUCTS, INC. 2003-02-11 US claimed
EP-1250043-A1 EXTENDED DURATION INSECT REPELLENT COMPOSITION AND METHOD OF APPLICATION TO THE SKIN AVON PRODUCTS, INC. (US) 2002-10-23 EP claimed
US-6440402-B1 Photostable sunscreen compositions and methods of stabilizing AVON PRODUCTS, INC. 2002-08-27 US claimed
WO-2002043491-A1 EXTENDED DURATION INSECT REPELLENT COMPOSITION AND METHOD OF APPLICATION TO THE SKIN AVON PRODUCTS, INC. (US) 2002-06-06 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090311208-A1 Oil In Silicone Emulsions and Compositions Containing Same CUTA, SRR, SMURF1 HPGD 2348/4885RAB9A 1712/4885SMN1; SMN2 382/4885
US-20030099679-A1 Extended duration insect repellent composition and method of application to the skin CUTA, ACHE, DAGLA HPGD 1332/4885RAB9A 3827/4885SMN1; SMN2 2519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.